Rich66
07-19-2010, 01:33 AM
Anticancer Res. (http://javascript%3cb%3e%3c/b%3E:AL_get%28this,%20%27jour%27,%20%27Anticancer% 20Res.%27%29;) 2010 May;30(5):1807-13.
Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer.
Rack B (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rack%20B%22%5BAuthor%5D), Jückstock J (http://www.ncbi.nlm.nih.gov/pubmed?term=%22J%C3%BCckstock%20J%22%5BAuthor%5D), Genss EM (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Genss%20EM%22%5BAuthor%5D), Schoberth A (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Schoberth%20A%22%5BAuthor%5D), Schindlbeck C (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Schindlbeck%20C%22%5BAuthor%5D), Strobl B (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Strobl%20B%22%5BAuthor%5D), Heinrigs M (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Heinrigs%20M%22%5BAuthor%5D), Rammel G (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rammel%20G%22%5BAuthor%5D), Zwingers T (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Zwingers%20T%22%5BAuthor%5D), Sommer H (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sommer%20H%22%5BAuthor%5D), Friese K (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Friese%20K%22%5BAuthor%5D), Janni W (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Janni%20W%22%5BAuthor%5D).
Department of Gynecology and Obstetrics, Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe, Campus Innenstadt, Ludwig-Maximilians-Universitaet, Muenchen, Germany. brigitte.rack@med.uni-muenchen.de
http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-standard-anticanres_full.gif (http://ar.iiarjournals.org/cgi/pmidlookup?view=long&pmid=20592383)
Abstract
BACKGROUND: There is strong evidence for the isolated tumour cells (ITCs) in the bone marrow of breast cancer patients having prognostic impact both at primary diagnosis and during recurrence-free follow-up. The goal of this study was to investigate the therapeutic efficacy of zoledronate on the persistence of ITC. PATIENTS AND METHODS: A total of 172 primary breast cancer patients without evidence of distant recurrence but detection of ITC in bone marrow were followed up. Zoledronate was administered every 4 weeks for 6 months to 31 patients who had completed surgery and adjuvant chemotherapy. In a matched-pair analysis, these patients were compared to 141 patients who did not receive additional zoledronate treatment. The bone marrow was re-examined after a median of 7.9 months (SD 0.89) and 11.5 months (SD 12.41; p=0.11), respectively. Patients were followed-up prospectively for a median of 39 months after the first aspiration. RESULTS: While ITCs were detected in all 172 patients at the time of first bone marrow aspiration, ITCs were detected in four patients (13%) following 6 months of zoledronate therapy in contrast to 38 patients (27%) of the control group (p=0.099). The reduction in cell numbers between the first and second aspiration reached statistical significance in the zoledronate group (p=0.02 vs. p=0.14). Persistent ITCs at the follow-up aspiration were associated with reduced recurrence-free survival (p=0.05). CONCLUSION: These results indicate a potential antineoplastic effect of the cell cycle-independent agent zoledronate on persisting ITCs in a dormant state.
PMID: 20592383 [PubMed - indexed for MEDLINE]
More on Zoledronic acid HERE (http://her2support.org/vbulletin/showthread.php?t=39563)
Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer.
Rack B (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rack%20B%22%5BAuthor%5D), Jückstock J (http://www.ncbi.nlm.nih.gov/pubmed?term=%22J%C3%BCckstock%20J%22%5BAuthor%5D), Genss EM (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Genss%20EM%22%5BAuthor%5D), Schoberth A (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Schoberth%20A%22%5BAuthor%5D), Schindlbeck C (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Schindlbeck%20C%22%5BAuthor%5D), Strobl B (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Strobl%20B%22%5BAuthor%5D), Heinrigs M (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Heinrigs%20M%22%5BAuthor%5D), Rammel G (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rammel%20G%22%5BAuthor%5D), Zwingers T (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Zwingers%20T%22%5BAuthor%5D), Sommer H (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sommer%20H%22%5BAuthor%5D), Friese K (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Friese%20K%22%5BAuthor%5D), Janni W (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Janni%20W%22%5BAuthor%5D).
Department of Gynecology and Obstetrics, Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe, Campus Innenstadt, Ludwig-Maximilians-Universitaet, Muenchen, Germany. brigitte.rack@med.uni-muenchen.de
http://www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--highwire.stanford.edu-icons-externalservices-pubmed-standard-anticanres_full.gif (http://ar.iiarjournals.org/cgi/pmidlookup?view=long&pmid=20592383)
Abstract
BACKGROUND: There is strong evidence for the isolated tumour cells (ITCs) in the bone marrow of breast cancer patients having prognostic impact both at primary diagnosis and during recurrence-free follow-up. The goal of this study was to investigate the therapeutic efficacy of zoledronate on the persistence of ITC. PATIENTS AND METHODS: A total of 172 primary breast cancer patients without evidence of distant recurrence but detection of ITC in bone marrow were followed up. Zoledronate was administered every 4 weeks for 6 months to 31 patients who had completed surgery and adjuvant chemotherapy. In a matched-pair analysis, these patients were compared to 141 patients who did not receive additional zoledronate treatment. The bone marrow was re-examined after a median of 7.9 months (SD 0.89) and 11.5 months (SD 12.41; p=0.11), respectively. Patients were followed-up prospectively for a median of 39 months after the first aspiration. RESULTS: While ITCs were detected in all 172 patients at the time of first bone marrow aspiration, ITCs were detected in four patients (13%) following 6 months of zoledronate therapy in contrast to 38 patients (27%) of the control group (p=0.099). The reduction in cell numbers between the first and second aspiration reached statistical significance in the zoledronate group (p=0.02 vs. p=0.14). Persistent ITCs at the follow-up aspiration were associated with reduced recurrence-free survival (p=0.05). CONCLUSION: These results indicate a potential antineoplastic effect of the cell cycle-independent agent zoledronate on persisting ITCs in a dormant state.
PMID: 20592383 [PubMed - indexed for MEDLINE]
More on Zoledronic acid HERE (http://her2support.org/vbulletin/showthread.php?t=39563)